Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1161-1180 of 3,900 trials

HER2-Low Metastatic Breast Cancer: DB-1303 vs Chemotherapy

We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.

Hormone Receptor Positive Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ongoing Treatment with Durvalumab for Cancer Patients

We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.

Advanced Non-Small Cell Lung CancerPost-Chemotherapy Urothelial CarcinomaExtensive Stage Small-Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

COVID-19 Vaccine: Preventing Type 1 Diabetes in At-Risk Children

We are studying if vaccinating children with a higher genetic risk for type 1 diabetes against COVID-19 can lower their chances of developing diabetes and related autoimmune conditions. This research aims to see if the vaccine can help protect their health.

Risk for Type 1 Diabetes>2 yearsMonitoring phase (IV)11-15 visitsStandard MedicinesCost ReimbursementEndocrinologyInfectious Diseases

Alzheimer's Disease Psychosis: ACP-204 Study

We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.

Alzheimer's Disease Psychosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Pulmonary Fibrosis: Long-Term Study of BI 1015550

We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Prosetin for Amyotrophic Lateral Sclerosis (ALS)

We are evaluating a new drug called Prosetin to see how safe it is and how well it is tolerated in people with ALS and healthy volunteers. This study aims to understand its effects on ALS symptoms.

Amyotrophic Lateral SclerosisSafety phase (I)Post-Trial Drug AccessNeurology

Pancreatic Cancer: Testing Enzyme Therapy

We are studying whether pancreatic enzyme replacement therapy can help patients with unresectable pancreatic cancer gain weight and improve their nutrition. This may enhance their quality of life and ability to handle chemotherapy.

Pancreatic Exocrine Insufficiency6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Generalized Myasthenia Gravis: Efgartigimod Safety Study

We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.

Myasthenia GravisEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Long-Term Safety Study of NTLA-2001

We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.

Hereditary Amyloidosis>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Thalassemia and Myelodysplastic Syndromes: SP-420 Treatment Study

We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.

Thalassemia and Myelodysplastic Syndromes6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Multiple Myeloma: Iberdomide with Isatuximab

We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Zolpidem Responses: Understanding Effects in Different Patients

We are investigating how zolpidem affects people with disorders of consciousness, vision impairments, and healthy volunteers. This study aims to uncover why some individuals respond differently to the medication.

Vision ImpairmentsDisorders of ConsciousnessHealthy Volunteers≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurologyPsychiatry

Chronic Obstructive Pulmonary Disease: New Inhaler Study

We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePulmonology

Advanced Solid Tumors: TAPISTRY Immuno-Oncology Study

We are testing a new treatment for patients with advanced or metastatic solid tumors that have specific genetic changes. The goal is to see how well it works and how it affects patients' daily lives.

Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Oral Vancomycin for Primary Sclerosing Cholangitis

We are studying whether oral vancomycin can improve liver health in adults and young patients with Primary Sclerosing Cholangitis. The trial will also look at the safety of the treatment and its effects on related health conditions.

Primary Sclerosing Cholangitis3-6 monthsEfficacy phase (II)Standard MedicinesGastroenterologyHepatology

Low Back Pain: PRGF-Endoret® Treatment Study

We are investigating whether PRGF-Endoret® can effectively reduce pain and enhance quality of life in patients with chronic low back pain due to disc degeneration, compared to standard treatments.

Low Back PainMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

B-Cell Malignancies: PIT565 Treatment Study

We are testing a new treatment called PIT565 for patients with relapsed or refractory B-cell malignancies. The goal is to see if it can improve outcomes for these patients.

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukaemia>2 yearsSafety phase (I)Oncology

Breast Cancer Surgery: Ketorolac and Pregabalin Study

We are exploring how preoperative use of ketorolac and pregabalin affects inflammation and pain in breast cancer patients. This study looks at how these effects may vary based on body weight.

Estrogen Receptor Positive Breast Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

COVID-19 Treatment: RECOVERY Trial

We are studying various treatments for COVID-19 to see if they can reduce death rates and help patients leave the hospital sooner. We also want to find out if these treatments can prevent severe breathing issues.

Pneumonia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Chronic Kidney Disease: CKD-bioMatch Study

We are exploring whether a new treatment based on biomarkers can improve kidney function in patients with chronic kidney disease compared to standard care. This study aims to find better ways to manage CKD and its effects.

Chronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrology